Company Overview - Hunan Maijizhi Biotechnology Co., Ltd. (Maijizhi) has submitted a listing application to the Hong Kong Stock Exchange, with CICC as the sole sponsor [1] - The company is a clinical-stage biopharmaceutical firm focused on discovering, developing, and commercializing innovative biologics to address unmet medical needs in allergic and autoimmune diseases [3] Product Pipeline - Since its establishment in 2016, Maijizhi has developed a robust pipeline of eight innovative candidate products, including core product MG-K10, key products MG-014 and MG-013, all of which are next-generation long-acting antibodies discovered and developed through the company's proprietary technology platform [3] - MG-K10 is a potential best-in-class, self-developed long-acting anti-IL-4Rα antibody currently undergoing clinical trials for eight indications, including atopic dermatitis and asthma, showing promising safety and efficacy data [3] Market Potential - The global market for allergic disease drugs is projected to grow from $61.8 billion in 2023 to $122.2 billion by 2032, with a compound annual growth rate (CAGR) of 7.9% [4] - The Chinese market for allergic disease drugs is expected to grow from $7.2 billion in 2023 to $31 billion by 2032, with a CAGR of 17.5% [4] - The global market for autoimmune disease drugs is anticipated to increase from $133.8 billion in 2023 to $192.3 billion by 2032, with a CAGR of 4.1% [4] - The Chinese autoimmune disease market is expected to grow significantly, from $3.8 billion in 2023 to $26.6 billion by 2032, with a CAGR of 24% [4] Financial Performance - For the fiscal year 2023, Maijizhi reported revenues of RMB 8.722 million, with total losses of approximately RMB 252.942 million [6][7] - In 2024, the company expects revenues to increase to RMB 24,000, while losses are projected to be around RMB 178.308 million [6][7] - The company has no approved or commercialized products yet but is advancing multiple candidates towards the BLA application stage [5]
新股消息 | 麦济生物递表港交所 目前并无任何已获批准或处于商业阶段的产品
智通财经网·2025-07-15 06:13